Recombinant murine interleukin (IL)-12 (rmIL-12) exhibits antitumor, antiviral, and antimicrobial activities and can modify allergic inflammatory reactions in animal models. Recombinant human IL-12 (rhIL-12) is currently in clinical trials for treatment of cancer, asthma, and viral hepatitis. Principally a phagocyte-derived cytokine, IL-12 targets natural killer cells and T lymphocytes, stimulating their activity and the secretion of interferon (IFN)-&gamma;. An understanding of the toxicology of IL-12, due in part to effects mediated by IFN-&gamma;, has emerged from preclinical safety and mechanistic studies and initial clinical trials. Target organs common to several animal species and humans include the lymphohematopoietic system, intestines, liver, and lung.
INTRODUCTION
Interleukin 12 (IL-12; natural killer [NK] cell stimulatory factor) is a heterodimeric cytokine produced by monocytes/macrophages, neutrophils, B cells, and dendritic cells in response to bacterial products, host cytokines, and other stimuli released during infections and cell-mediated immune reactions (9, 13, 31, 35, 48, 56, 59) . Activation of T lymphocytes and NK cells by IL-12 is accompanied by synthesis and release of interferon (lr-FN)--y, probably independently of the pathway involving IL-18 (IFN-~y inducing factor) (4, 17, 36, 38, 61) . IL-12 sends a powerful signal to naive precursor cells of the Thelper (Th) lineage, directing differentiation toward Thl cells and thereby shifting an evolving immune response towards cell-mediated immunity (41, 54) .
Recombinant murine IL-12 (rmIL-12) or murine IL-12 cDNA has been employed in a variety of mouse models, with demonstrated efficacy in promoting antimicrobial (20, 30, 34, 43, 60, 62) , antimycotic (61) , and antiparasitic activity (15) , inducing regression in tumor models (3, 7, 10, 57) , and ameliorating pulmonary allergic responses (by shifting Th2 responses toward Thl-like cytokine profiles) (49) .
Preclinical toxicity assessments in mice (8, 16, 33) , guinea pigs (23) , squirrel monkeys (45) , cynomolgus macaques (23, 33) , and chimpanzees (T. Anderson, personal communication) have documented adverse IL-12-induced hematopoietic, intestinal, hepatic, and pulmonary effects. The target tissues of IL-12 in various species are summarized in Table I . An overlapping spectrum of changes with those observed in animals has been reported for humans in clinical trials with IL-12 (11, 33) . The immunobiology of IL-12 has been extensively reviewed (24, 34, 54, 55) .
HUMAN CLINICAL TRIALS
Severe toxicity, including 2 deaths, has been associated with treatment of renal carcinoma patients receiving 500 ng/kg/day of rhIL-12 (11, 33) . Phase I and phase II clinical trials have resulted in the determination of safer dosing regimens, thereby establishing a wider therapeutic window (33) . Common adverse events reported in human trials for the treatment of cancer (renal cell cancer and melanoma) and viral diseases (human hepatitis B virus [HBV] and human hepatitis C virus [HCV]) include flulike symptoms, a rapid transient leukopenia, elevated liver transaminases, gastrointestinal toxicity, and/or liver dysfunction. A single dose of IL-12 given 14 days prior to cycles of 5 consecutive doses of 500 ng/kg/day reduced plasma IFN-~y levels and the severe manifestations of IL-12-induced toxicity (33) .
CHIMPANZEE STUDIES
Uninfected chimpanzees (Pan troglodytes) or those infected with HBV or HCV were treated subcutaneously with rhIL-12 for 12 wk. Two HCV-infected chimpanzees died during the study; I had acute blood loss from the lower intestinal tract and necrotizing hepatitis, and the other had chronic proliferative pneumonia, fibrinonecrotic pleuritis, epicarditis, and pericarditis. Hepatic regenerative hyperplasia was noted in a third animal. Treatment-related pathologic changes included anemia, thrombocytopenia, and elevated serum transaminase activity and coagulation parameters. There were no significant findings in rhIL-12-dosed uninfected and HBV-infected chimpanzees (T Anderson, personal communication).
SQUIRREL MONKEY STUDIES
Because rhIL-12 is pharmacologically active in squirrel monkeys (Sciureus saimiri), these animals were utilized in preclinical safety evaluations, thus reducing the total rhIL-12 required to complete a safety study compared with that required when using larger macaque species. High doses of rhIL-12 (~10 pLg/kg/day) induced e Lesions ranged from hypocellularity to hyperplasia with peripheral cytopenias. f Lesions ranged from intra-and extravascular accumulations of leukocytes and pulmonary edema to interstitial pneumonia. strong neutralizing antibody responses in squirrel monkeys after 12-14 days (45). Significant hematologic changes evident after 2 wk of dosing with rhIL-12 included mild to moderate anemia and leukocytosis. IL-12 also induced serum chemistry alterations characterized by hypoproteinemia, hypoalbuminemia, hypophosphatemia, and hypocalcemia. Macroscopic findings in 2 squirrel monkeys dosed with 50 jig/kg of IL-12 per day included pulmonary edema and pleural and peritoneal effusions. In addition, generalized dose-dependent lymph node enlargement and splenomegaly occurred in monkeys dosed with rhIL-12. Dose-related microscopic findings included thymic cortical atrophy, splenic lymphoid hyperplasia with histiocytic infiltration and extramedullary hematopoiesis within the red pulp, Kupffer cell hypertrophy and hyperplasia, trilineage bone marrow hyperplasia, and reactive hyperplasia of lymph nodes. Pulmonary lesions were characterized by striking intravascular accumulations of mononuclear cells (45) . IFN-y may contribute to the development of intravascular leukocytosis through the upregulation of mononuclear cell-specific endothelial cell adhesion molecules.
Thickening of glomerular basement membranes was observed in IL-12-dosed squirrel monkeys (45) and IFN-'Y&horbar;dosed cynomolgus macaques (Macaca fascicularis) (51) . Basement membrane thickening was not due to immune complex deposition and was reversible in IFN-ydosed macaques (51) . Glomerular lesions have not been observed in IL-12 dosed macaques (25, 45) .
CYNOMOLGUS MACAQUE STUDIES
Cynomolgus macaques given 1 J,Lg/kg/day of rhIL-12 by intravenous bolus or subcutaneous injection for 5 days developed a transient decrease in total leukocyte counts due to lymphopenia and monocytopenia. Reversible thrombocytopenia and anemia were also noted (6, 33) . Plasma neopterin concentrations were increased in IL-12treated groups compared to controls (6) . Neopterin is a pteridine pathway intermediate released by macrophages and other cells. The detection of elevated neopterin concentrations in plasma or urine is consistent with an ongoing cell-mediated immune response. Clinical signs observed in IL-12-dosed macaques included fatigue, anorexia, and episodes of emesis and diarrhea. A low incidence of gastric congestion, ulcerative colitis and ileitis, and lymphadenitis of Peyer's patches was observed. The toxic effects of IL-12 in cynomolgus macaques were mitigated by a single dose of IL-12 administered 14 days before the initiation of 5 consecutive days of dosing. The reduced toxicity associated with this dosing regimen was correlated with reduced plasma IFN-q levels (33) . When administered to macaques 3 times/wk for 2 wk by subcutaneous injection at doses of 1 or 10 (JLg/kg/day (rhIL-12, Ro 24-7472), Kupffer cell hypertrophy and hyperplasia, mononuclear cell infiltration of sinusoids, and hepatocellular necrosis, splenic and thymic lymphocyte depletion, and infiltration of lymph nodes were observed (23) .
MOUSE STUDIES
The spectrum of toxicity induced by IL-12 in mice is partly strain dependent. C3H/Hej mice dosed subcutaneously with 0.5 jig/day of rmIL-12 exhibited macroscopic changes, including emaciation, fluid-filled intestines, splenic enlargement, skeletal and cardiac muscle necrosis, and pleural and/or peritoneal effusions (33) . Microscopic changes included hyperplastic and degenerative gastroenteropathy, hepatic sinusoidal histiocytosis with multifocal histocytic aggregates and small foci of hepatic necrosis, reticuloendothelial cell hyperplasia in the spleen and lymphoid tissues, hematopoietic tissue hyperplasia, and skeletal and cardiac muscle necrosis (33) . Other treatment-related changes included lymphopenia, hypoalbuminemia, and liver enzyme elevations. Administration of 0.5 jig of rmIL-12 per day to C3H/Hej mice resulted in a high incidence of mortality (33) . Mice predosed with 0.5 pLg of IL-12 7 days prior to initiation of daily dosing had a decreased severity of lesions and an increased survival rate, which was correlated with a reduction in serum IFN-q concentrations (33) . In outbred CD-1 (BR) ICR mice dosed intraperitoneally with 1 or 10 )JLg of rmIL-12 per day for 14 days, a greater incidence of skeletal muscle necrosis was noted in males than in females (22) .
Intraperitoneal injection of 129/Sv mice with 1 pLg/day for 4-7 days reproduced the anemia, body and liver weight changes, and splenic and lymph node pathology observed in C3H/Hej and CD-1 mice (8, 16, 22, 33) . Lymphopenia, neutropenia, and anemia with reticulocytopenia were prominent hematologic findings in IL-12dosed 129/Sv mice (16) . IL-i 2 reduced bone marrow col-ony-forming counts (CFC) for erythroid (E), granulocytic-myeloid (GM), and multilineage (multi) committed hematopoietic progenitor cells, as determined in methyl cellulose semiliquid cultures. Erythroid progenitors were particularly sensitive to IL-12 administration (16) . Studies in nude mice suggest that the effects of rmIL-12 on the erythron may be mediated by T cells (T. Anderson, personal communication). In addition to generalized bone marrow hypoplasia, there were increased monocytes and their precursors in bone marrow and an increased myeloblast count. An increase in splenic CFC-E, CFC-GM, and CFCmulti was reflected in the extramedulary hematopoiesis noted on histologic examinations of spleens of IL-12-dosed mice (16) . IL-12 appears to induce a reversible shift of hematopoiesis from bone marrow to spleen (16, 50) . Splenic extramedullary hematopoiesis, however, does not compensate for suppression of bone marrow hematopoiesis in mice.
Notably absent from the IL-12-induced spectrum of pathologic alterations documented in 129/Sv mice were skeletal and cardiac muscle necrosis and prominent gastrointestinal toxicity (8) . An altered Thl/Th2 balance in 129/Sv mice may account, at least in part, for the observed differences. The 129/Sv and related C57BL/6 mice but not C3H/Hej mice are deficient in the inducible isoenzyme phospholipase A2, which would potentially blunt prostanoid contributions to mononuclear cell-induced tissue injury (29) . Prostaglandin E2 production by activated macrophages is considered one potentially important IL-12-and IFN-y-induced second messenger required for Th2 differentiation (26) .
GUINEA PIG STUDIES
Histologic alterations in guinea pigs dosed subcutaneously with 40, 200, or 400 jjLg/kg/day of rhIL-12 (Ro 24-7472) were similar to those observed in cynomolgus macaques and included hepatocellular necrosis, Kupffer cell hyperplasia, lymphocyte depletion in thymus, spleen, and lymph nodes, interstitial inflammation of the kidneys, mononuclear cell infiltration of liver and heart (with myofibril necrosis), pancreatic atrophy, and gastric erosion in several males (23) .
THE PATHOGENESIS OF IL-12-INDUCED TOXICITY
In IL-12-dosed humans, cynomolgus monkeys, and mice, serum levels of IFN-q are markedly elevated, presumably because of NK and T-cell activation (6, 8, 17, 33) . IFN-y has a powerful enhancing effect on the ability of phagocytic cells to produce IL-12 (35) . This strong positive feedback mechanism likely promotes local antimicrobial activity at sites of infection but may exacerbate the development of toxicity with exogenous administration. The spectrum of toxicity associated with IL-12 administration in mice, monkeys, and humans in clinical trials is similar to that induced by IFN-y treatment in the same species (8, 32, 33, 51) ; it is characterized by hematopoietic suppression and intestinal toxicity. In addition, serum concentrations of tumor necrosis factor (TNF)-a, sTNFR-P75, and corticosterone were elevated in IL-12-treated virus-challenged mice (34, 39) . However, TNF-a was not increased in 2 additional studies (8, 33) . Because the priming of macrophage responses by IFN-y is characterized by induction of competency for I TNF-a production and increased cell surface TNFR-P50 and TNFR-P75 expression (1, 44) , IFN-q and TNF-a may contribute in a synergistic fashion to the constellation of IL-12-induced toxicities. The presence of splenic macrophage infiltrates, activated Kupffer cells, and elevated plasma neopterin levels are consistent with persistent stimulation of the monocyte-macrophage system by IFN-~y and/or other IL-12-induced cytokines.
To test the hypothesis that the toxicology of IL-12 is in part due to the synthesis and secretion of high levels of secondary cytokines, IFN-y receptor-deficient (IFN-y R-I-) 129/Sv mice were dosed with 1 pLg/kg/day of rmIL-12 for 4 days (8, 16, 27) . In contrast to wild-type 129/Sv mice, hematopoietic toxicity was not observed in IFN-y R-/mice (16) . Enhanced levels of committed bone marrow hematopoietic progenitor cells were present in IL-12-dosed IFN-~y R-'mice (16) . Although these experiments suggest that the hematopoietic toxicity of IL-12 in mice results directly from IFN-y, the administration of erythropoietin and granulocyte colony-stimulating factor (CSF) appears to partially mitigate the effects of IL-12 on erythropoiesis and myelopoiesis in wild-type mice (18, 19) . Because one of the functions of these cytokines is lineage-specific inhibition of apotosis, reversal of IL-12-induced myelotoxicity may involve inhibition of IFN-y-induced apoptotic signals. In vitro hematopoiesis studies with IL-12 that are not confounded by secondary IFN-~y production have demonstrated that IL-12 promotes proliferation in a synergistic fashion with IL-3, FLT3 ligand, and kit ligand (Steel factor) (5, 28, 42) , confirming a stimulatory hematopoietic function for IL-12.
Consistent with the mitigated expression of IL-12-induced hematopoietic suppression in IFN-y R-/is the abrogation of the multiple and somewhat differing toxicities in IL-12-dosed C3H/Hej mice that have received neutralizing antibodies to IFN-y. Severe pulmonary edema occured in IL-12-dosed IFN-y R-'mice but not in wildtype mice, suggesting a unique toxic potential for IL-12 in this strain of mouse. In another study, in which IFN-y Razz and wild-type mice were dosed subcutaneously for 14 days with 50 ~,g/kg/day, similar lesions were observed in wild type to knockout mice but with a greater degree of severity and more rapid onset in the IFN-q R-1-mice (25) . Related vascular-leak syndromes have been observed in IL-2-dosed mice (2) and granulocyte-macrophage CSF-deficient mice (14, 47) . The pulmonary histology of IFN-y R mice and squirrel monkeys dosed with IL-12 is similar; however, mononuclear cell accumulations are reported to be interstitial in mice and intravascular in monkeys (8, 45) . Mononuclear cell accumulations in IFN-q R-/and R +/+ mice were comprised of macrophages, B cells, and CD4-and CD8-positive T cells, with greater numbers of B cells and CD4-positive T cells in IFN-y R-1mice, and were accompanied by an upregulation of Vascular Cell Adhesion Molecule (VCAM-1) expression (25) .
The most severe toxicity and/or deaths in cynomolgus macaques, squirrel monkeys, and chimpanzees occurred with dosing regimens that resulted in greater than doseproportional exposure and net accumulation of IL-12. In general, doses below those resulting in accumulation of IL-12 were better tolerated. IMMUNOTOXICOLOGY IL-12 is of pathogenetic importance in autoimmune diseases with cellular immune responses characterized by Thl-cytokine profiles (49, 52) . Rodent models of diabetes (53) , rheumatoid arthritis (37), multiple sclerosis (46), graft-versus-host disease (GVHD) (58) , and lymphocytic choriomeningitis (39) require IL-12 for expression of disease or demonstrate disease exacerbation following IL-12 administration. The common mechanism of exacerbation appears to be promotion of the cell-mediated immune responses underlying the pathology of these autoimmune diseases. The widespread expression and upregulation of major histocompatiblity complex class II molecules on cells resulting from IL-12-induced IFN--Y upregulation (8) permit more efficient antigen presentation and facilitate CD4 lymphocyte function, thereby allowing the potential exacerbation of autoimmune disease processes (21, 41, 52) . Therefore, the dosing of IL-12 in patients with autoimmune disorders or cell-mediated immune responses such as graft rejection reactions or GVHD must be undertaken cautiously. The pharmacologic neutralization of IL-12 has been suggested for the treatment of autoimmune and immune-mediated diseases (52) . CONCLUSION -IL-12 produces a spectrum of pathologic alterations largely overlapping with those documented for IFN-y. Studies conducted with IFN-y-neutralizing antibodies, mice deficient in the IFN-q receptor, and dosing regimens that reduce high plasma IFN-y concentrations confirm that much of the acute toxicity of IL-12 is IFN-y dependent. The therapeutic window for IL-12 may be considerably greater than that of IFN-~y, particularly when a priming dose of IL-12 is given prior to initiation of consecutive daily dosing. The lowering of plasma IFN-q concentrations may, however, decrease efficacy, as suggested from studies in mice (12, 40) . Optimal therapeutic regimens for rhIL-12 will need to be established clinically.
